Neuren Pharmaceuticals NURPF Stock
Neuren Pharmaceuticals Price Chart
Neuren Pharmaceuticals NURPF Financial and Trading Overview
| Neuren Pharmaceuticals stock price | 13.36 USD |
| Previous Close | 9.01 USD |
| Open | 8.86 USD |
| Bid | 0 USD x 0 |
| Ask | 0 USD x 0 |
| Day's Range | 8.86 - 8.86 USD |
| 52 Week Range | 2.4 - 9.52 USD |
| Volume | 629 USD |
| Avg. Volume | 629 USD |
| Market Cap | 1.14B USD |
| Beta (5Y Monthly) | 1.637931 |
| PE Ratio (TTM) | Infinity |
| EPS (TTM) | 0.78 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
NURPF Valuation Measures
| Enterprise Value | 1.09B USD |
| Trailing P/E | Infinity |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 74.1155 |
| Price/Book (mrq) | 26.848482 |
| Enterprise Value/Revenue | 70.97 |
| Enterprise Value/EBITDA | -1515.431 |
Trading Information
Neuren Pharmaceuticals Stock Price History
| Beta (5Y Monthly) | 1.637931 |
| 52-Week Change | 240.76% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 9.52 USD |
| 52 Week Low | 2.4 USD |
| 50-Day Moving Average | 9.15 USD |
| 200-Day Moving Average | 6.37 USD |
NURPF Share Statistics
| Avg. Volume (3 month) | 629 USD |
| Avg. Daily Volume (10-Days) | 1.57K USD |
| Shares Outstanding | 128.97M |
| Float | 105.67M |
| Short Ratio | N/A |
| % Held by Insiders | 16.80% |
| % Held by Institutions | 12.19% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:20 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 1.19% |
| Operating Margin (ttm) | -4.74% |
| Gross Margin | 17.54% |
| EBITDA Margin | -4.68% |
Management Effectiveness
| Return on Assets (ttm) | -1.098% |
| Return on Equity (ttm) | 0.45% |
Income Statement
| Revenue (ttm) | 15.42M USD |
| Revenue Per Share (ttm) | 0.12 USD |
| Quarterly Revenue Growth (yoy) | 382.19% |
| Gross Profit (ttm) | 2.71M USD |
| EBITDA | -722000 USD |
| Net Income Avi to Common (ttm) | 184K USD |
| Diluted EPS (ttm) | 0 |
| Quarterly Earnings Growth (yoy) | 4157.60% |
Balance Sheet
| Total Cash (mrq) | 40.18M USD |
| Total Cash Per Share (mrq) | 0.32 USD |
| Total Debt (mrq) | 0 USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 25.772 |
| Book Value Per Share (mrq) | 0.33 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 3.6M USD |
| Levered Free Cash Flow (ttm) | 2.59M USD |
Profile of Neuren Pharmaceuticals
| Country | United States |
| State | VIC |
| City | Camberwell |
| Address | 697 Burke Road |
| ZIP | 3124 |
| Phone | 61 3 9092 0480 |
| Website | https://www.neurenpharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. Neuren Pharmaceuticals Limited was incorporated in 2001 and is based in Camberwell, Australia.
Q&A For Neuren Pharmaceuticals Stock
What is a current NURPF stock price?
Neuren Pharmaceuticals NURPF stock price today per share is 13.36 USD.
How to purchase Neuren Pharmaceuticals stock?
You can buy NURPF shares on the Other OTC exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Neuren Pharmaceuticals?
The stock symbol or ticker of Neuren Pharmaceuticals is NURPF.
Which industry does the Neuren Pharmaceuticals company belong to?
The Neuren Pharmaceuticals industry is Biotechnology.
How many shares does Neuren Pharmaceuticals have in circulation?
The max supply of Neuren Pharmaceuticals shares is 132.05M.
What is Neuren Pharmaceuticals Price to Earnings Ratio (PE Ratio)?
Neuren Pharmaceuticals PE Ratio is 17.12820600 now.
What was Neuren Pharmaceuticals earnings per share over the trailing 12 months (TTM)?
Neuren Pharmaceuticals EPS is 0.78 USD over the trailing 12 months.
Which sector does the Neuren Pharmaceuticals company belong to?
The Neuren Pharmaceuticals sector is Healthcare.